Summary
This filing is an amendment (10-K/A) to Amgen Inc.'s previously filed Annual Report on Form 10-K for the fiscal year ended December 31, 2012. The amendment specifically pertains to Exhibit 10.54, a Collaboration and License Agreement between Amgen and Celltech R&D Limited. The company sought confidential treatment for portions of this exhibit and is refiling it with reduced redactions following discussions with the SEC staff. This amendment does not alter other financial information or disclosures from the original 10-K and is primarily administrative in nature, re-establishing the exhibit with revised confidentiality status.
Financial Highlights
55 data pointsBeta
Financial Statements
Beta
| Revenue | $17.27B |
| Cost of Revenue | $3.20B |
| Gross Profit | $14.07B |
| SG&A Expenses | $4.81B |
| Operating Expenses | $11.69B |
| Operating Income | $5.58B |
| Interest Expense | $1.05B |
| Net Income | $4.34B |
| EPS (Basic) | $5.61 |
| EPS (Diluted) | $5.52 |
| Shares Outstanding (Basic) | 775.00M |
| Shares Outstanding (Diluted) | 787.00M |
Key Highlights
- 1This is an Amendment No. 1 to the Form 10-K for the fiscal year ended December 31, 2012.
- 2The sole purpose of this amendment is to refile Exhibit 10.54, a Collaboration and License Agreement with Celltech R&D Limited, with less redacted information.
- 3The amendment addresses the confidential treatment of specific portions of Exhibit 10.54, following SEC staff correspondence.
- 4This filing does not amend any other information or financial statements presented in the original Form 10-K.
- 5New certifications from the CEO and CFO are included as required by Rule 13a-14(a).
- 6The amendment supersedes the previously filed version of Exhibit 10.54.
- 7Amgen Inc. is identified as a large accelerated filer.
Frequently Asked Questions
The primary reason for this filing is to amend Exhibit 10.54, a Collaboration and License Agreement with Celltech R&D Limited, by refiling it with reduced redactions. This action was taken after Amgen sought and received guidance from the SEC staff regarding the confidential treatment of certain portions of the agreement.
No, this amendment is purely administrative and pertains to the disclosure of specific contractual information (Exhibit 10.54). It does not modify or update any of the financial statements or operational disclosures made in the original Form 10-K filing for the year ended December 31, 2012.
Exhibit 10.54 is the Collaboration and License Agreement between Amgen Inc. and Celltech R&D Limited, dated May 10, 2002, along with its Amendment No. 1, effective June 9, 2003. This amendment reflects a revised version of this exhibit with less information redacted, as originally requested by Amgen for confidential treatment.
No, this filing is not intended to provide new financial results or operational updates. It is solely an amendment to correct the redaction level of a specific exhibit related to a prior agreement. All other disclosures from the original Form 10-K remain as filed.